

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Diagnosics Advisory Committee (DAC)

### Minutes of the Meeting on Wednesday 4 July

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

#### **PRESENT:**

##### **Standing Committee members:**

Professor Adrian Newland (Chairman)  
Professor Chris Hyde  
Mr Christopher Wiltsher  
Dr Diego Ossa  
Professor Ian Cree  
Ms Margaret Ogden  
Professor Mark Sculpher  
Professor Noor Kalsheker  
Dr Paul Collinson  
Mr Paul Weinberger  
Dr Simon Fleming  
Dr Steve Thomas  
Dr Sue Crawford  
Dr Trevor Cole

##### **Standing Committee apologies:**

Dr Erika Denton  
Professor Lisa Hall  
Dr Mark Kroese  
Dr Richard Nicholas  
Professor Ron Akehurst  
Mr Stuart Saw

#### **Depth of anaesthesia monitors – BispectralIndex(BIS), E-Entropy and Narcotrend-Compact M**

##### **Specialist Committee members:**

Dr Andrew Smith  
Dr David Smith  
Dr John Andrzejowski  
Mr John Hitchman  
Professor Michael Wang

##### **Specialist Committee members apologies:**

Professor Anthony Fisher

**In attendance: DAP staff**

Nick Crabb, Associate Director  
Hanan Bell, Technical Adviser  
Sarah Byron, Technical Analyst  
Frances Nixon, Technical Analyst  
Farouk Saeed, Technical Analyst  
Jackson Lynn, Project Manager  
Bushra Hussain, Administrator  
David Lyons, Temporary Administrative Support

**External Assessment Group representatives – Southampton Health Technology Assessments Centre (SHTAC)**

Jeremy Jones  
Jonathan Shepherd

**Observing**

Andy Stainthorpe, Associate Director, Patient Access Schemes Liaison Unit  
Chris Pomfrett, Technical Adviser, Medical Technologies Evaluation Programme  
Helen Barnett, Senior Medical Editor  
Laura Norburn, Project Manager, Patient and Public Involvement Programme  
Leeza Osipenko, Senior Scientific Adviser  
Sarah Gage, Coordinator, Meetings in Public

*Note: The order in which the Committee took items of business at the meeting differed from the agenda. The minutes record the actual sequence of items, numbered according to the agenda.*

**PART 1 AND PART 2 (open and closed parts of the meeting).  
10.30am – Part 1 open session commenced.**

**1. Introduction to the meeting**

The Chair welcomed Committee members and observers.

The Chair welcomed representatives from Coviden UKI & Norden, GE Healthcare Clinical Systems (UK) Ltd and Narcotrend to the the meeting.

Apologies were noted.

**2. Code of conduct for members of the public attending the meeting**

The Chairman explained the code of conduct to the members of the public attending this meeting.

**3. Any other business**

No other business was offered.

#### **4. Minutes from the last Committee meeting**

The Committee agreed the minutes from the Wednesday 6 June Committee meeting.

#### **5. NICE's advisory body guide to declaring a conflict of interest**

The Chairman drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

#### **6. Depth of anaesthesia monitors –BispectralIndex(BIS), E-Entropy and Narcotrend-Compact M - Draft Guidance**

### **Part 1 – Open session**

The Chair informed all attendees that Professor Ron Akehurst has declared interests and is conflicted therefore he is not taking part in this meeting.

The Chair requested any conflicts of interest to be stated. Dr David Smith and Dr John Andrzejowski declared their conflicts, this did not mean they were unable to participate in the meeting.

The Chair introduced Technical Analyst, Sarah Byron to discuss with the committee the consideration of public consultation comments on Depth of anaesthesia monitors –BispectralIndex(BIS), E-Entropy and Narcotrend-Compact M

The Committee was asked if there were any specific equalities to consider in relation to this technology.

The Chair asked the representatives of the manufacturers to comment on any matters of factual accuracy.

There were no public attendees.

The Chair then thanked the experts and manufacturer representatives for their attendance, participation and contribution to the Assessment and they left the meeting.

The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

### **Part 2 – closed session**

The Committee instructed the technical team to prepare the Diagnostics Consultation Document (DCD) in line with their decisions.

**SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption**

**Specialist Committee members:**

Dr Matthew Brookes  
Dr Annelies Maenhout  
Professor John McLaughlin  
Dr Kevin Bradley  
Dr Nick Read  
Dr Richard Thompson

**External Assessment Group representatives: Kleijnen Systematic Reviews Ltd**

Hans Severens  
Maiwenn Al  
Marie Westwood

**PART 1 AND PART 2 (open and closed parts of the meeting).  
13:15 – Part 1 open session commenced.**

**7. Introduction to the meeting**

The Chair welcomed Committee members and observers.

The Chair welcomed the representative from GE Healthcare, Manufacturer to the meeting.

Apologies were noted

**8. Any other business**

No other business was offered.

**9. NICE's advisory body guide to declaring a conflict of interest**

The Chairman drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

The Chair informed all attendees that Professor Ron Akehurst has declared interests and is conflicted therefore he is not taking part in this meeting.

The Chair asked Committee members to declare any relevant interests.

**10. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption - Final Recommendations**

***The Chair introduced the following presentations:***

The Chair introduced presentations from the Lead Team members:

- Professor Chris Hyde – Standing Committee Member
- Dr Matthew Brookes – Specialist Committee Member

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of SeHCA (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption

The Chair asked the Committee to consider any Equality issues in relation to these technologies.

The Chair asked the representatives of the manufacturer to comment on any matters of factual accuracy.

There was one public member who attended this meeting.

The Chair then thanked the manufacturer representative for their attendance, participation and contribution to the Assessment and they left the meeting

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

## **Part 2 – closed session**

The Committee instructed the technical team to prepare the Diagnostics Consultation Document (DCD) in line with their decisions.

## **Date, time and venue of next meeting**

**Tuesday 4 September, 10:00 at National Institute for Health and Clinical Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD**